News & Press Releases

Thomas Lynch chairs former colleague’s cancer startup

In 2012, five years before he became the CSO of Bristol-Myers Squibb, Thomas Lynch began hearing from a Yale colleague about new ways to fight cancer with antibodies. Now that colleague, David Spiegel, has a relatively new company centered around those antibodies — Kleo Pharmaceuticals — and Lynch will be joining as chairman of the board.


Print Friendly, PDF & Email

Upcoming Events:

October 2020
No event found!